Editas Medicine (EDIT)
(Delayed Data from NSDQ)
$5.22 USD
-0.13 (-2.43%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $5.25 +0.03 (0.57%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Editas Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 78 | 20 | 26 | 91 | 21 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 78 | 20 | 26 | 91 | 21 |
Selling & Adminstrative & Depr. & Amort Expenses | 247 | 246 | 219 | 226 | 161 |
Income After Depreciation & Amortization | -169 | -226 | -193 | -135 | -141 |
Non-Operating Income | 16 | 4 | 2 | 3 | 0 |
Interest Expense | 0 | -1 | 2 | -16 | -7 |
Pretax Income | -153 | -220 | -193 | -116 | -134 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -153 | -220 | -193 | -116 | -134 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -153 | -220 | -193 | -116 | -134 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -168 | -220 | -188 | -131 | -138 |
Depreciation & Amortization (Cash Flow) | 1 | 6 | 5 | 4 | 3 |
Income After Depreciation & Amortization | -169 | -226 | -193 | -135 | -141 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 75.97 | 68.67 | 67.62 | 58.61 | 49.98 |
Diluted EPS Before Non-Recurring Items | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 |
Diluted Net EPS (GAAP) | -2.02 | -3.21 | -2.85 | -1.98 | -2.68 |
Fiscal Year end for Editas Medicine, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 60.05 | 5.34 | 2.89 | 9.85 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 60.05 | 5.34 | 2.89 | 9.85 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 84.02 | 55.50 | 46.98 | 60.81 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -23.97 | -50.16 | -44.09 | -50.96 |
Non-Operating Income | NA | 3.50 | 5.14 | 3.81 | 3.51 |
Interest Expense | NA | -1.59 | 0.00 | 0.01 | 1.58 |
Pretax Income | NA | -18.87 | -45.02 | -40.29 | -49.04 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -18.87 | -45.02 | -40.29 | -49.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -18.87 | -45.02 | -40.29 | -49.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 81.71 | 81.65 | 71.38 | 68.92 |
Diluted EPS Before Non-Recurring Items | NA | -0.23 | -0.55 | -0.56 | -0.71 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.55 | -0.56 | -0.71 |